Fujii A, Oka N, Murata Y, Higuchi A, Itoh N, Nakagawa J, Tanaka H, Izumi T, Yamada Y
Department of Urology, Hyogo Medical Center for Adult Disease.
Nihon Hinyokika Gakkai Zasshi. 1992 May;83(5):619-26. doi: 10.5980/jpnjurol1989.83.619.
Twenty-three patients with bladder cancer (TCC; 18 patients, SCC; 5 patients) were treated with adjuvant chemotherapy (day 1: methotrexate 20 mg/m2, vincristine 0.6 mg/m2, cyclophosphamide 500 mg/m2, adriamycin 20 mg/m2, bleomycin 30 mg, day 2: cisplatinum 50 mg/m2; MVP-CAB). A total of 3 cycles of MVP-CAB were given as preoperative or postoperative therapy. The following results were obtained. Group 1 (purpose to preserve the bladder, preoperative MVP-CAB): Four of 7 patients achieved a partial response. It was possible to perform bladder preservation surgery in 3 of these 4 patients. All 3 patients had pedunculated, solitary tumors, and there was no carcinoma in situ. Group 2 (purpose to improve the prognosis; preoperative MVP-CAB): Hydronephrosis did not resolve in the 4 patients with this complication. They received total cystectomy, and 2 patients died of cancer 23 months later. Group 3 (purpose to improve the prognosis; postoperative MVP-CAB): Ten of 12 patients (total cystectomy; 10 patients, partial cystectomy; 2 patients) survived disease-free for an average of 17 months (5-44 months), 1 patient developed recurrence 12 months later, and 1 patient died of cancer 6 months later. The 1-year survival rate in Group 3 was 86% for TCC, 100% for SCC, 80% for grade 3 TCC, and 89% for pT2 or more advanced cancer.
23例膀胱癌患者（移行细胞癌18例，鳞状细胞癌5例）接受了辅助化疗（第1天：甲氨蝶呤20mg/m²、长春新碱0.6mg/m²、环磷酰胺500mg/m²、阿霉素20mg/m²、博来霉素30mg，第2天：顺铂50mg/m²；MVP - CAB方案）。共给予3个周期的MVP - CAB方案作为术前或术后治疗。获得以下结果。第1组（目的是保留膀胱，术前MVP - CAB方案）：7例患者中有4例获得部分缓解。这4例患者中有3例可行膀胱保留手术。所有3例患者均为有蒂孤立肿瘤，且无原位癌。第2组（目的是改善预后；术前MVP - CAB方案）：4例有肾盂积水并发症的患者积水未缓解。他们接受了全膀胱切除术，2例患者在23个月后死于癌症。第3组（目的是改善预后；术后MVP - CAB方案）：12例患者（全膀胱切除术10例，部分膀胱切除术2例）中有10例无病生存，平均生存17个月（5 - 44个月），1例患者在12个月后复发，1例患者在6个月后死于癌症。第3组中移行细胞癌的1年生存率为86%，鳞状细胞癌为100%，3级移行细胞癌为80%，pT2或更晚期癌症为89%。
